Stay updated with breaking news from Start Vaccinating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. expects to have enough coronavirus vaccine to meet U.S. demand by May despite a planned pause in the use of Johnson & Johnson’s shot pending a review of rare blood clots. J&J said it’s delaying its rollout in Europe.
France Halts Brazil Flights; NYC Reschedules Shots: Virus Update Bloomberg 17 mins ago Bloomberg News (Bloomberg) -- The U.S. expects to have enough coronavirus vaccine to meet U.S. demand by May despite a planned pause in the use of Johnson & Johnson’s shot pending a review of rare blood clots. J&J said it’s delaying its rollout in Europe. German Chancellor Angela Merkel’s cabinet approved a law setting nationwide rules on virus restrictions after some regions failed to impose curbs despite rising cases. Italy is in talks to set up vaccine production hubs as the gover...
The U.S. expects to have enough vaccine to meet demand by May despite a planned pause in the use of Johnson & Johnson’s shot pending a review of rare blood clots. J&J said it’s delaying its rollout in Europe.
U.S. President Joe Biden said the U.S. may have enough vaccine for every adult American by the end of May as Merck & Co. Inc. confirmed it will help make rival Johnson & Johnson’s shot. He said he hopes the nation can return to normal a year from now.
U.S. President Joe Biden said the U.S. may have enough vaccine for every adult American by the end of May as Merck & Co. Inc. confirmed it will help make rival Johnson & Johnson’s shot. He said he hopes the nation can return to normal a year from now.